Completed × Melanoma × Breast × Clear all
NCT06171945 2025-10-27

AYAConnect

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
63 enrolled
NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
145 enrolled 47 charts
NCT03154190 2025-01-24

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Stanford University

Phase NA Completed
128 enrolled 24 charts
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
NCT04604158 2024-05-21

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

Cedars-Sinai Medical Center

Phase NA Completed
38 enrolled
NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
NCT00020267 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT01624220 2023-12-05

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

M.D. Anderson Cancer Center

Phase NA Completed
41 enrolled
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
NCT03849469 2023-03-30

DUET-4

Xencor, Inc.

Phase 1 Completed
78 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT01272817 2022-11-23

Mini-allo

Scripps Health

Phase NA Completed
36 enrolled
NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
52 enrolled 25 charts